Literature DB >> 29519861

Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban.

Ida Martinelli1, Maria Abbattista2, Paolo Bucciarelli2, Armando Tripodi2,3, Andrea Artoni2, Francesca Gianniello2, Cristina Novembrino2,3,4, Flora Peyvandi2,3,4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29519861      PMCID： PMC6029544          DOI： 10.3324/haematol.2017.185132

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.

Authors:  Mark A Crowther; Jeff S Ginsberg; Jim Julian; Judah Denburg; Jack Hirsh; James Douketis; Carl Laskin; Paul Fortin; David Anderson; Clive Kearon; Ann Clarke; William Geerts; Melissa Forgie; David Green; Lorrie Costantini; Wendy Yacura; Sarah Wilson; Michael Gent; Michael J Kovacs
Journal:  N Engl J Med       Date:  2003-09-18       Impact factor: 91.245

2.  Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies.

Authors:  G Ruiz-Irastorza; M J Cuadrado; I Ruiz-Arruza; R Brey; M Crowther; R Derksen; D Erkan; S Krilis; S Machin; V Pengo; S Pierangeli; M Tektonidou; M Khamashta
Journal:  Lupus       Date:  2011-02       Impact factor: 2.911

3.  Antiphospholipid antibodies, recurrent thromboembolism, and intensity of warfarin anticoagulation.

Authors:  P Prandoni; P Simioni; A Girolami
Journal:  Thromb Haemost       Date:  1996-05       Impact factor: 5.249

4.  Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH.

Authors:  K M J Devreese; S S Pierangeli; B de Laat; A Tripodi; T Atsumi; T L Ortel
Journal:  J Thromb Haemost       Date:  2014-05       Impact factor: 5.824

5.  The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome.

Authors:  Katarzyna Malec; Tadeusz Góralczyk; Anetta Undas
Journal:  Thromb Res       Date:  2016-12-14       Impact factor: 3.944

6.  A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS).

Authors:  G Finazzi; R Marchioli; V Brancaccio; P Schinco; F Wisloff; J Musial; F Baudo; M Berrettini; S Testa; A D'Angelo; G Tognoni; T Barbui
Journal:  J Thromb Haemost       Date:  2005-05       Impact factor: 5.824

Review 7.  Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature.

Authors:  Virginie Dufrost; Jessie Risse; Stéphane Zuily; Denis Wahl
Journal:  Curr Rheumatol Rep       Date:  2016-12       Impact factor: 4.592

Review 8.  Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome.

Authors:  Nicolas Noel; Fabien Dutasta; Nathalie Costedoat-Chalumeau; Boris Bienvenu; Xavier Mariette; Loik Geffray; Damien Sene; Rafik Bekhadj Chaidi; Jean-Marie Michot; Olivier Fain; Luc Darnige; Annick Ankri; Patrice Cacoub; Jean-Charles Piette; David Saadoun
Journal:  Autoimmun Rev       Date:  2015-04-09       Impact factor: 9.754

9.  Clinical course of high-risk patients diagnosed with antiphospholipid syndrome.

Authors:  V Pengo; A Ruffatti; C Legnani; P Gresele; D Barcellona; N Erba; S Testa; F Marongiu; E Bison; G Denas; A Banzato; S Padayattil Jose; S Iliceto
Journal:  J Thromb Haemost       Date:  2009-10-30       Impact factor: 5.824

10.  Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.

Authors:  Hannah Cohen; Beverley J Hunt; Maria Efthymiou; Deepa R J Arachchillage; Ian J Mackie; Simon Clawson; Yvonne Sylvestre; Samuel J Machin; Maria L Bertolaccini; Maria Ruiz-Castellano; Nicola Muirhead; Caroline J Doré; Munther Khamashta; David A Isenberg
Journal:  Lancet Haematol       Date:  2016-09       Impact factor: 18.959
View more
  6 in total

1.  Recurrent venous thromboembolism after discontinuation of rivaroxaban therapy in a patient with antiphospholipid syndrome.

Authors:  Shusuke Yagi; Seiichi Nishiyama; Toshio Abe; Masataka Sata
Journal:  BMJ Case Rep       Date:  2019-01-10

2.  Primary antiphospholipid syndrome in a hemodialysis patient with recurrent thrombosis of arteriovenous fistulas.

Authors:  Nikola Gjorgjievski; Pavlina Dzekova-Vidimliski
Journal:  J Bras Nefrol       Date:  2019-07-29

3.  Crassolide Suppresses Dendritic Cell Maturation and Attenuates Experimental Antiphospholipid Syndrome.

Authors:  Chi-Chien Lin; Yu-Kang Chang; Shih-Chao Lin; Jui-Hsin Su; Ya-Hsuan Chao; Kuo-Tung Tang
Journal:  Molecules       Date:  2021-04-24       Impact factor: 4.411

4.  Thromboembolic Antiphospholipid Syndrome (APS): Efficacy and Safety of Different Anticoagulants-Results of the APSantiCO Registry.

Authors:  Annabel Schulz; Eva Herrmann; Olivia Ott; Edelgard Lindhoff-Last
Journal:  J Clin Med       Date:  2022-08-18       Impact factor: 4.964

5.  Sex Differences in Clinical Characteristics and Prognosis in Primary Thrombotic Antiphospholipid Syndrome.

Authors:  Yongfa Huang; Huazhen Liu; Wanting Qi; Le Du; Mengtao Li; Xiaofeng Zeng; Xiaoxiao Guo; Jiuliang Zhao; Shuyang Zhang
Journal:  Front Cardiovasc Med       Date:  2022-07-04

6.  Evaluation of the Validity of SAMe-TT2R2 Score in a Cohort of Venous Thromboembolism Patients Treated With Warfarin.

Authors:  Eman Nawash Alhmoud; Hazem Elewa; Mohammed S Abdul Gelil; Osama B Abd El Samad; Abdelnasser Y Elzouki
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.